News

The post-doctoral diabetes research program will be fully funded by Novo Nordisk. In this program, a total of 12 post-doctoral researchers will be offered a three-year grant to

The agreement will give Boehringer access to VTU’s yield-enhancing Pichia pastoris expression platform to develop and manufacture therapeutic proteins. The platform is based on VTU’s AOX1 promoter libraries

The Janssen decision to advance ADU-741 toward clinical trials was based on preclinical data generated in the first eight months of the collaboration. This accomplishment triggered a milestone

ADS-5102 is initially being developed by Adamas for the treatment of levodopa-induced dyskinesia (LID) in patients with Parkinson’s disease. ADS-5102, an investigational agent, is a long-acting, extended-release capsule

The results are highlighted today in a poster presentation titled, "Novel oral RORgamma agonists demonstrate anti-tumor efficacy in the 4T1 breast cancer model," with lead author, Jacques Moisan,

These funds represent the first closing of a Series B venture financing round, the proceeds from which will be used to advance a series of clinical programs and

The partnership will support local and global sponsors looking to bring generic and innovative drugs to the Brazilian market by offering one stop shopping and joint expertise in

AIT-CF is designed to deliver a high dose formulation (160 ppm) to the lungs using positive air pressure and integrated monitoring parameters. The new delivery system has the

Doryx (doxycycline hyclate delayed-release tablets) is a tetracycline-class antimicrobial designed as adjunctive therapy for severe acne. Actavis EVP Commercial, North American Brands William Meury said: "Actavis currently licenses